Cetrorelix diacetate
Based on 2 publication(s) in Google Scholar
Cetrorelix (SB-75) diacetate is a competitive gonadotropin-releasing hormone receptor (GnRHR) antagonist with a Kd of 0.19 nM. Cetrorelix diacetate inhibits the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), thereby suppressing the secretion of downstream sex steroids. Cetrorelix diacetate prevents ovulation, induces reversible reproductive shutdown and azoospermia, reduces ovarian fibrosis, improves superovulation outcomes, and inhibits chemotherapy-induced mitochondria-dependent apoptosis. Cetrorelix diacetate is applicable for fertility assistance research.
For research use only. We do not sell to patients.
- CAS No.: 130143-01-0
- Formula: C74H100ClN17O18
- Molecular Weight:1551.14
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Cetrorelix diacetate
More
Biological Activity
Description
In Vitro
Cetrorelix does not inhibit EGF-stimulated proliferation of human granulosa cells at pharmacologically relevant concentrations, with inhibitory effects only seen at ~100-fold higher concentrations[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Cetrorelix (5 μg/day; i.p.; daily; 20 days) alone has no detectable effect on ovarian granulosa cell apoptosis, hormone levels, or mitochondrial function in healthy female Sprague-Dawley rats[1].
Cetrorelix (~10 μg/kg; s.c.; single dose) immediately suppresses plasma LH by >80% in male castrated rats, with full recovery within 24 hours[3].
Cetrorelix (250-1250 μg/kg; s.c.; single dose) immediately suppresses LH in male castrated cynomolgus monkeys, with suppression lasting for at least 96 hours[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sprague-Dawley (female, 250 g)[1]
-
Dosage:5 μg/day (pretreatment); 5 μg/day + 20 mg/kg/day (combined with alkylating antineoplastic agent)
-
Administration:i.p.; daily; 10 days (pretreatment); i.p.; daily; 10 days (combined)
-
Result:Reduced granulosa cell apoptotic index from 13.6% to 3.1%.
Restored serum estradiol levels from ~80 pg/mL to ~160 pg/mL.
Preserved normal granulosa cell ultrastructure including intact mitochondria.
Reversed alkylating antineoplastic agent-induced mitochondrial depolarization, resulting in a green fluorescence intensity of 15.36, red fluorescence intensity of 23.16, and a red/green ratio of 1.51.
Inhibited alkylating antineoplastic agent-induced cytochrome c release from mitochondria to cytoplasm.
Suppressed alkylating antineoplastic agent-induced increases in Bax-positive cells from 90% to 25%, caspase-3-positive cells from 85% to 30%, and cytochrome c-positive cells from 80% to 30%.
Restored alkylating antineoplastic agent-reduced Bcl-2-positive cells from 40% to 70%.
-
Animal Model:Sprague-Dawley (female, 250 g)[1]
-
Dosage:5 μg/day
-
Administration:i.p.; daily; 20 days
-
Result:Did not alter granulosa cell apoptotic index (2.8%, similar to control's 2.5%).
Did not change serum estradiol or progesterone levels.
Did not affect granulosa cell ultrastructure, mitochondrial membrane potential, cytochrome c distribution between mitochondria and cytoplasm, or expression levels of Bax, Bcl-2, caspase-3, or cytochrome c.
-
Animal Model:C57BL/6J (female, 52 weeks old, aged)[2]
-
Dosage:5 µg/kg (3 doses over 1 week); 5 µg/kg (7 doses over 1 week)
-
Administration:i.p.; once every 3 days (3 doses over 1 week); daily (7 doses over 1 week)
-
Result:Increased mean total oocyte count to 13.2 (3-dose group) and 11.4 (7-dose group), with normal oocyte counts increased to 9.8 (74.2% normal rate) and 8.7 (76.3% normal rate), respectively, compared to controls (P<0.05).
Achieved fertilization rates of 96.9% (3-dose group) and 88.5% (7-dose group), with birth rates of 58.3% and 51.8%, respectively, comparable to control values.
Reduced ovarian fibrosis, with phalloidin-positive area percentage decreased compared to untreated aged controls (P<0.05).
Showed no significant difference in ovary weight compared to control aged mice.
-
Animal Model:Male castrated rats[3]
-
Dosage:2.5 μg/rat (~10 μg/kg)
-
Administration:s.c.; single dose
-
Result:Suppressed plasma LH concentrations immediately, reaching a nadir at 4 hours with an >80% fall in LH concentrations.
Returned serum LH to normal levels within 24 hours.
-
Animal Model:Male castrated cynomolgus monkeys (*Macaca fascicularis*)[3]
-
Dosage:250 μg/kg; 625 μg/kg; 1250 μg/kg
-
Administration:s.c.; single dose
-
Result:Suppressed LH concentrations immediately across all doses, reaching a nadir at ~12 hours post-injection.
Maintained LH concentrations suppressed for at least 96 hours.
Showed no LH rebound within the 96-hour interval at any dose.
- Fibrosis/Collagen Morphometry
- Reproductive and Developmental Toxicity Study
- Collagen: Sirius Red Staining
- Detection of Apoptosis
- TUNEL staining for apoptotic DNA fragmentation
- Annexin V plus membrane-impermeant dye apoptosis staining
- Research Protocol for Endocrine Diseases
- Connective Tissue: Masson's Trichrome/Collagen Trichrome Staining
- Apoptosis Solutions
Chemical Information
-
CAS No. 130143-01-0
-
Molecular Weight 1551.14
-
Formula C74H100ClN17O18
-
Synonyms
SB-75 diacetate
-
Sequence Shortening
Ac-{2-Naph-Ala}-{Cl-Phe}-{3Py-Ala}-SY-{Cit}-LRPA-NH2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Commun Biol
Diurnal testosterone oscillations gate drug delivery via phase separation of ZO-1 at the blood-testis barrier in mice. [Abstract]2026 Jun 1. PMID: 42219451 -
Gen Comp Endocrinol
Neuromodulatory effects of GnRH on the caudal neurosecretory Dahlgren cells in female olive flounder. [Abstract]2021 Jun 1:307:113754. PMID: 33711313
Purity & Documentation
References
[1]. Zhao XJ, et al. GnRH antagonist cetrorelix inhibits mitochondria-dependent apoptosis triggered by chemotherapy in granulosa cells of rats. Gynecologic oncology. 2010 Jul;118(1):69-75. [Content Brief]
[2]. Kanda A, et al. Effect of Cetrorelix administration on ovarian stimulation in aged mice. Experimental animals. 2021 Feb 06;70(1):31-36. [Content Brief]
[3]. Reissmann T, et al. The LHRH antagonist cetrorelix: a review. Human reproduction update. 2000;6(4):322-31. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- Cetrorelix diacetate
- 130143-01-0
- SB-75 diacetate
- GnRH Receptor
- Apoptosis
- cynomolgus monkeys
- pituitary cells
- gonadotropin-releasing hormone receptor
- Sprague-Dawley rats
- human granulosa cells
- luteinizing hormone
- rat mast cells
- epidermal growth factor
- follicle-stimulating hormone
- C57BL/6J mice
- Inhibitor
- inhibitor
- inhibit